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Abstract
Characterization of the mechanism(s) of androgen-driven human angiogenesis could have significant implications for
modeling new forms of anti-angiogenic therapies for CaP and for developing targeted adjuvant therapies to improve
efficacy of androgen-deprivation therapy. However, models of angiogenesis by human endothelial cells localized within an
intact human prostate tissue architecture are until now extremely limited. This report characterizes the burst of
angiogenesis by endogenous human blood vessels in primary xenografts of fresh surgical specimens of benign prostate or
prostate cancer (CaP) tissue that occurs between Days 6–14 after transplantation into SCID mice pre-implanted with
testosterone pellets. The wave of human angiogenesis was preceded by androgen-mediated up-regulation of VEGF-A
expression in the stromal compartment. The neo-vessel network anastomosed to the host mouse vascular system between
Days 6–10 post-transplantation, the angiogenic response ceased by Day 15, and by Day 30 the vasculature had matured and
stabilized, as indicated by a lack of leakage of serum components into the interstitial tissue space and by association of
nascent endothelial cells with mural cells/pericytes. The angiogenic wave was concurrent with the appearance of a reactive
stroma phenotype, as determined by staining for a-SMA, Vimentin, Tenascin, Calponin, Desmin and Masson’s trichrome, but
the reactive stroma phenotype appeared to be largely independent of androgen availability. Transplantation-induced
angiogenesis by endogenous human endothelial cells present in primary xenografts of benign and malignant human
prostate tissue was preceded by induction of androgen-driven expression of VEGF by the prostate stroma, and was
concurrent with and the appearance of a reactive stroma phenotype. Androgen-modulated expression of VEGF-A appeared
to be a causal regulator of angiogenesis, and possibly of stromal activation, in human prostate xenografts.
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Introduction
Angiogenesis, the formation of new capillaries from pre-existing
blood vessels, providesoxygenandnutrients fororganogenesis during
fetal development and homeostasis of adult tissue, as well as for
survival and proliferation of cancer cells, functions crucial for
organism and tumor growth [1,2]. Increased microvessel density
(MVD) in tumor tissue has been correlated with increased tumor
stage,tumorgrade,metastasis,anddecreasedcancer-specificsurvival.
Therefore, MVD in prostate cancer (CaP) has been investigated as a
potential prognostic marker for identification of patients at high risk
of progression and recurrence after radical prostatectomy [3,4,5,6,7].
The viability, integrity and proliferative potential of human prostate
endothelial cells, as in other organs, were demonstrated to depend on
circulating androgens and on VEGF expression [7,8,9,10]. However,
the constitutive production of VEGF in human prostate appeared
modulated by androgen, suggesting that AR-mediated expression of
VEGF may regulate the balance between vascular stability and
angiogenesis in the prostate vascular network [8,11,12].
Therapeutic inhibition of neo-vessel formation during progres-
sion of CaP offers hope for reducing morbidity and mortality.
However, the promising results of anti-angiogenic therapeutics
generated in animal models, or xenografts of human tumor cell
lines transplanted into animals, have not predicted effectiveness in
human patients. Angiogenesis within the tumor microenvironment
is a complex process regulated by pro- and anti-angiogenic factors
produced by both tumor epithelial cells and the stromal
compartment [13,14]. Consequently, conspicuous limitations of
xenograft models based on implantation of permanent cultures of
human tumor cells into immune-compromised mouse hosts
include that the neo-vasculature of the xenografts is of mouse
host origin, and that the neo-vessels develop and mature in
response to a hybrid signaling milieu that emanates from both the
host stromal microenvironment and the human tumor cells. These
compromises are exacerbated in cell-line based prostate cancer
xenografts by their inability to model the unique biological
characteristics of human prostate vasculature, that human prostate
endothelial cells demonstrate the highest proliferative index, and
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vascular bed in the human body [8], and that the prostate
endothelial cells express AR [15]. Therefore, a major factor that
has limited development of appropriate independent, or adjuvant,
anti-angiogenesis therapies for prostate cancer, or for most solid
tumors, is a lack of pre-clinical models for analysis of human tumor
vascular dynamics responding to an intact human tumor
microenvironment. This study describes the dynamics of human
angiogenesis that occurs in primary xenografts of human prostate
tissue, either benign or prostate cancer tissue, transplanted to
immuno-compromised (SCID) mice pre-implanted with a source
of systemic androgen to maintain human serum levels of
testosterone. Moreover, the human prostate primary xenograft
model provides a unique tool for evaluation of the individual
contributions of the endothelial compartment, the epithelial/
cancer epithelial compartment, and the stromal compartment, to
androgen-mediated homeostasis, or angiogenesis, of human
prostate microvascular endothelial cells.
Materials and Methods
Clinical Specimens
Anonymous/de-identified human prostate and kidney remnant
surgical tissue specimens were collected from patients, through a
written consent, and processed in accordance with NIH guidelines
for the use of human subjects, with approval by the IRB of Roswell
Park Cancer Institute (RPCI). Benign prostate tissue for
transplantation as primary xenografts was harvested from
prostates removed surgically during cystoprostatectomy surgery,
or from uninvolved areas of prostates harvested by radical
prostatectomy. Normal kidney tissue was harvested from unin-
volved areas of kidneys removed during radical nephrectomy
surgery. CaP and RCC tissues for transplantation as xenografts
were harvested from cores taken through palpable tumors
removed during radical prostatectomy or radical nephrectomy
surgery, respectively, and verified in a frozen section by a surgical
pathologist before release from pathology. Tissue specimens were
released by pathology for transplantation within two hours of the
interruption of the blood supply to the prostate during surgery
[16]. Pathology verified tissue specimens were submerged
immediately in ice-cold ViaSpan solution (Barr Laboratories,
Inc., Pomona, NY), and transported on ice for transplantation. An
initial tissue (IT) specimen of at least 8 mm
3 was removed as a
control from each surgical tissue sample before transplantation,
and was fixed in 10% formalin, and paraffin embedded for
histological evaluation.
Primary Xenografts of Intact Human Tissue
Xenografts were established by transplantation of intact pieces
of prostate and kidney tissue as described previously [17,18]. All
experimental protocols that involved laboratory animals were
performed in accordance with National Institutes of Health
guidelines and were approved by the Institutional Animal Care
and Use Committee of RPCI (IACUC #: 1044M). In brief, 3–5
days before transplantation of tissue, 3 month-old male SCID
BALB/c mice were castrated and implanted subcutaneously with
sustained-release testosterone pellets (12.5 mg; Innovative Re-
search of America, Sarasota, FL) to maintain serum testosterone
levels of ,4.0 ng/ml throughout the study. Serum testosterone
levels in the host were measured using a testosterone enzyme-
linked immunosorbent assay (ELISA, Immuno-Biological Labo-
ratories Inc, Minneapolis, MN). Surgical tissue specimens were
cut into wedge-shaped pieces 2–3 mm in length and 1–2 mm in
width, the tissue wedges dipped in Matrigel, the tissue pieces
inserted individually into the subcutaneous compartment
through small incisions on the right and left flanks of mouse
hosts (4–5 xenografts per flank, with a maximal total of 8–10
xenografts per host), and the incision sites closed with Nexband
tissue glue (Veterinary Products Laboratories, Phoenix, AZ). At
selected times after transplantation, host animals were eutha-
nized and the xenografts harvested for analysis: Days 1, 2, 3, 4,
7, 10, 14 and 30 after tissue transplantation. For analysis of the
effect of circulating androgens on angiogenesis, xenografts also
were implanted into castrated mouse hosts not implanted with
supplemental testosterone pellets. Harvested xenografts either
were frozen in OCT, or were fixed in 10% formalin for a
minimum of 24 hrs, paraffin-embedded and sectioned (5.0 mm)
onto ProbeOn Plus slides (Fisher Scientific International,
Suwanee, GA).
Immunohistochemical (IHC) Analyses
Formalin-fixed, paraffin-embedded sections of initial surgical
tissue specimens (IT), or of primary xenografts, from benign and
malignant human prostate tissue, benign human kidney tissue
and RCC tissue were hydrated by sequential steps through Citri-
solv (Fisher, Suwanee, GA) and a graded series of alcohol washes.
After antigen retrieval with Citra Buffer (BioGenex, San Ramon,
CA), endogenous peroxidase activity was blocked before
incubation with primary antibody. After blocking, tissue sections
were incubated overnight with antibodies against human CD31
(huCD31: 1:40, Dako, Carpinteria, CA), huCD34 (1:100,
Neomarkers, Fremont, CA), msCD31 (1:100, PECAM-1; BD
PharMingen, Bedford, MA), von Willebrand (1:100, Biogenex,
San Ramon, CA), AR (N-20) (1:100, Santa Cruz Biotechnology,
Santa Cruz, CA), Ki-67 (1:1500, Novocastra, New Castle, UK),
Pan cytokeratin (1:200, Sigma-Aldrich, Saint Louis, MO),
prostate specific antigen (PSA) (1:100 Dako, Carpinteria, CA)
VEGF-A (1:100, Neomarkers, Fremont, CA), VEGFR2 (1:20,
Sigma, Saint Louis, MO), a-smooth muscle actin (1:200, Dako,
Carpinteria, CA), Calponin (1:5000, Sigma-Aldrich, Saint Louis,
MO), Tenascin (1:5000, Sigma-Aldrich, Saint Louis, MO),
Desmin (1:500, Sigma-Aldrich, Saint Louis, MO), Vimentin
(1:200, Dako, Carpinteria, CA), GLUT1 (1:500, Alpha diagnos-
tic, San Antonio, TX), HIF-1a and HIF-2a (1:100, Novus
Biologicals, Littleton, CO). All antibodies were diluted in 10 mM
Tris-HCl buffer (pH 7.8) that contained 8.4 mM sodium
phosphate, 3.5 mM potassium phosphate, 120 mM NaCl, and
1.0% BSA (w/v). After incubation with primary antibody, tissue
sections were washed 3 times in Tris-HCl buffer (pH 7.8) for
10 min each, and incubated with HRP-conjugated anti-rabbit
IgG or anti-mouse IgG (1:100, DakoCytomation) for 2 h at room
temperature. Peroxidase activity was developed using 100 mM
Tris-HCl buffer that contained 3,3-diaminobenzidine tetra-
hydrochloride (1.0 mg/ml, Sigma-Aldrich) and H2O2 (1.0 ml/
ml, VWR International, West Chester, PA). Hematoxylin (Harris)
was used as a nuclear counter-stain in tissue sections. Stained
slides were dehydrated by sequential steps through a graded series
of alcohol washes and Citrisolv (Fisher, Suwanee, GA), and were
mounted using cover slips. For immuno-fluorescence studies,
after incubation with primary antibody the specimens were
incubated for 2 hrs with AlexaFluor488- or AlexaFluor594-
conjugated affinity-purified donkey anti-rat or anti-mouse IgG
(1:200, Molecular Probes, Eugene, OR) secondary antibody at
room temperature. DAPI (49,69-diamidino-2-phenylindole dihy-
drochloride) was used to counterstain nuclei for immunofluores-
cence studies. IHC or immunofluorescence staining in the
absence of primary antibody, or using pre-immune serum,
provided negative controls.
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Vascular Perfusion
Vasculature of primary xenografts of prostate tissue was
visualized through intra-vital binding of fluorescently labeled
lectins administered systemically, as described previously [19].
Mice were anesthetized with ketamine (100 mg/kg i.p.) plus
xylazine (10 mg/kg i.p.), FITC-labeled L. esculentum lectin (100 ml
1.0 mg/ml in 0.9% NaCl; Vector Laboratories, Burlingame, CA)
injected into the tail vein, and the lectin allowed to circulate
through the mouse vascular system for 5 minutes. At the
conclusion of the incubation, the chest was opened and the
complete vascular volume replaced by perfusion with fixative (1%
paraformaldehyde in PBS, pH 7.4) for 2 minutes at a pressure of
120 mmHg administered through an 18-gauge cannula inserted
into the aorta via an incision in the left ventricle. Blood and
fixative exited through an opening cut into the right atrium. Fixed
xenograft tissues were removed, frozen in OCT, and processed for
IHC.
Determination of hypoxic areas
Animals were administered pimonidazole hydrochloride (Hy-
poxyprobe
TM-1, HPI, Burlington, MA) via intra-peritoneal
injection (60 mg/100 gm body weight). One hour after injection,
prostate xenografts were harvested, formalin fixed, paraffin-
embedded, sectioned, and hypoxic areas visualized using IHC
with a mouse monoclonal antibody that detected pimonidazole
adducts (MAb1 1:100, HPI, Burlington, MA). For positive controls
of tissue hypoxia, xenografts harvested from animals previously
administered pimonidazole were place in an hypoxia chamber
(Invivo2 400, Ruskinn, Pencoed, UK) for 1 hr before fixation.
RT-PCR Analysis of Gene Expression
Total RNA from initial tissue specimens (IT) of human prostate
tissue, and from prostate xenografts harvested on different days
after transplantation, was prepared using the RNAeasy mini-kit
(QIAGEN, Inc., Valencia, CA). Reverse transcription (RT) of
mRNA was performed using the SuperScript III First-Strand kit
(Invitrogen). Approximately 1.0 ml of reverse transcribed cDNA
product was used as template in the Platinum PCR Supermix
(Invitrogen) reaction mix that contained specific primer sets
(200 nM). PCR products were separated using electrophoresis in
2% agarose gels and bands visualized with SYBR green gel stain
(Molecular Probes). Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) was used as a loading control in analytical gels. Primer
sequences for the PCRs were: VEGF-A, forward 59-ATGAC-
GAGGGCCTGGAGTGTG-39 and reverse 59- CCTATGTG-
CTGGCCTTGGTGAG-39; bFGF, forward 59-TCACCACGC-
TGCCCGCCTTGC-39 and reverse 59-CAGTTCGTTTCAGT-
GCCACAT-39; IL-8, forward 59-ATGACTTCCAAGCTGGC-
CGTGGCT-39 and reverse 59- TCTCAGCCCTCTTCAAAA-
ACTTCTC-39; IL-6, forward 59-AGCTCAGCTATGAACTCC-
TTCTC-39 and reverse 59-GTCTCCTCATTGAATCCAGAT-
TGG-39; TGF-b, forward 59-AAGGACCTCGGCTGGAAGTG-
39 and reverse 59-CCCGGGTTATGCTGGTTGTA-39; IGF-1,
forward 59-CCTCCTCGCATCTCTTCTACCTG-39 and re-
verse 59- CTGCTGGAGCCATACCCTGTG -39 and GAPDH,
forward 59-GGAAGGTGAAGGTCGGAGTCA-39 and reverse
59- GTCATTGATGGCAACAATATCCACT -39.
Digital Image Analysis
Digital images of immuno-histochemically and immuno-fluor-
escently stained sections of IT specimens, and of primary
xenografts of benign and malignant human prostate and kidney
tissues, were collected using a Hamamatsu 3CCD color camera
mounted on an Axioskop microscope (Carl Zeiss, Inc., Thorn-
wood, NY). Digital image analysis was performed using ImageJ
software (Research Services Branch, National Institute of Mental
Health, Bethesda, MD). Five fields (0.4 mm
2) from each xenograft
were analyzed to determine the average number of vessels per field
(microvessel density=MVD) and the average number of vessels
per field that contained at least one proliferating endothelial cell
(expressing Ki-67).
Statistical Analysis
Descriptive statistics, Student’s paired, unpaired t tests, and data
correlations were performed using Microsoft Excel 2000 (Micro-
soft Corp., Redmond, WA) or Prism 3 (GraphPad Software, Inc.,
San Diego, CA) using a 95% confidence interval. Average MVD,
PMVD and MVA were graphed 6 SE.
Results
Primary Xenografts of Human Prostate Tissue Undergo a
Burst of Human Angiogenesis After Transplantation
Mouse hosts were castrated and pre-implanted with slow release
testosterone pellets, to establish human levels of serum testoster-
one, and subsequently were transplanted with human benign
prostate tissue, or prostate cancer tissue. The morphology and
function of the individual prostate cellular compartments were
evaluated histologically and by IHC over the initial fourteen days
after transplantation. The in vivo tissue architecture and inter-
compartmental cell signaling milieu were preserved in primary
xenografts of both benign and malignant prostate tissue for the
entire duration of the study. The glandular epithelial cell
compartment in the primary xenografts maintained expression
of three markers of prostate epithelial cell differentiation, two of
which depend on androgen-mediated signaling (AR and PSA)
(Fig. 1). The lack of necrosis, and the maintenance of expression of
AR and PSA, over the entire fourteen-day time-course after
transplantation suggested the small size of the xenografts allowed
efficient diffusion of oxygen, nutrients and androgens from the
host mouse circulation into the xenografts, even before anasto-
mosis of the xenograft and host vascular systems.
Three-dimensional reconstruction of serial optical sections
collected by confocal laser scanning microscopic visualization of
fluorescently-labeled anti-huCD31 antibody in primary xenografts
of human benign and prostate cancer tissues demonstrated a
dramatic increase in the number of vessels over the 14 days after
transplantation compared to the corresponding initial tissue (IT)
specimen before transplantation (Fig. 2a, b). The neo-vessels in
prostate xenografts harvested on Day 14 after transplantation were
abundant, tortuous, and of variable diameter (Fig. 2b). The small-
to-medium caliber neo-vessels were dispersed throughout the
xenografts, in contrast to vasculature in the IT specimen that
predominantly was localized adjacent to glandular structures.
Analysis of the species of origin of the endothelial cells in the neo-
vessels involved in the angiogenic response during the 14 days after
transplantation was performed by dual-immunostaining using
species-specific antibodies for CD31 conjugated with different
fluorochromes. The vast majority of vessels localized within
prostate xenografts, whether endogenous, or newly formed during
the angiogenic wave, were lined with human endothelial cells and
lacked host endothelial cells (Fig. 2c, green staining). Vasculature
of host origin, in contrast, was present at the periphery of the
human prostate xenografts, localized predominantly to the cuff of
compressed host tissue that surrounded the xenografts, with host
Angiogenesis in Human Prostate Xenografts
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staining).
Time Course of Angiogenesis, Anastomosis and
Maturation of the Newly Formed Vessels
Immuno-histochemical staining for the endothelial cell markers
human CD31 (huCD31) (Fig. 3), CD34 and vWF (not shown) in
primary xenografts of human benign prostate tissue and prostate
cancer tissue demonstrated a dramatic increase in microvessel
density (MVD) during the 14 days after transplantation (Fig. 3b–g)
as compared to the MVD in the corresponding initial tissue
specimen harvested before transplantation (Fig. 3a). In contrast to
the peri-glandular localization of vessels in the initial tissue
specimen, a time course analysis of neo-vascularization revealed
that nascent vessels lined with huCD31 expressing cells were
dispersed throughout the stromal compartment by Days 5–7 after
transplantation, and the MVD increased progressively through
Day 14. Quantification of MVD in xenografts demonstrated a
consistent 5–7 fold increase in the MVD of human endothelial
cell-lined vessels compared to the corresponding initial tissue
specimen (Fig. 3h open circles, Fig. 3i, bars with diagonal lines).
The marked increase in MVD occurred between Days 7 and 14
after transplantation; the MVD plateaued after Day 14 and
remained at this level for at least 60 days (Fig. 3i, bars with
horizontal lines). The angiogenic response in primary xenografts of
human prostate tissue induced by transplantation, in both benign
and malignant prostate tissue, was prostate tissue specific.
Transplantation of fresh surgical tissues from benign kidney or
RCC, a highly vascular tumor characterized by high rates of
endothelial cell proliferation, was performed as a comparison for
the angiogenic response observed in primary xenografts of the
relatively avascular prostate tissue. However, neither xenografts of
benign human renal tissue nor RCC tissue demonstrated an
increase in MVD compared to the MVD of the initial tissue
specimen (Fig. 3h,i - black circles and bars). Notably, the MVD in
primary xenografts of benign renal tissue and RCC were similar
on Day 14 after transplantation, but was approximately ten-fold
higher than the MVD of the IT prostate tissue specimens.
However, on Day 14 after transplantation, the MVD of prostate
xenografts, as a result of vigorous angiogenesis, approached that
observed for RCC xenografts (Fig. 3h).
Proliferative activity of the human endothelial cells during the
angiogenic wave was quantitated by IHC using co-localization of
huCD31 and the marker of proliferation, Ki-67 (Fig. 4a).
Endothelial cell proliferation was evaluated quantitatively during
the 14 days after transplantation of xenografts into mouse hosts as
the percent of vessels that contained at least a single Ki-67 positive
endothelial cell (Fig. 4b). The peak of endothelial cell proliferation
occurred between Days 4 and 10 after transplantation, with
proliferation in the endothelial cell compartment returning to pre-
transplantation levels by Day 14 (Fig. 4b). Therefore, the increase
in MVD observed between Days 5 and 14 after transplantation
was correlated temporally with an increased proliferative index in
the human endothelial cells.
In the human prostate gland, angiogenesis has been correlated
with the presence of androgen, which suggests AR-mediated
regulation [12,20,21,22]. The role of androgen stimulation in the
angiogenic wave in primary xenografts of human prostate tissue
was characterized by a temporal comparison of changes in MVD
in xenografts transplanted to hosts pre-implanted with continuous
Figure 1. Primary xenografts of human prostate tissue maintain the in vivo tissue architecture and expression of key prostatic
markers. Immuno-histochemical identification of protein expression of androgen receptor (AR), prostate-specific antigen (PSA) and pan-cytokeratin
(Cyt) visualized by peroxidase staining demonstrated the level of expression remained constant over the fourteen days post-transplantation (1–14).
doi:10.1371/journal.pone.0029623.g001
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transplanted into castrate mouse hosts that were not pre-implanted
with testosterone pellets. Figure 4c demonstrates a substantial
difference in MVD at Day 14 post-transplantation between
xenografts transplanted into mouse hosts with (d14+T), or without
(d14-T), testosterone stimulation. Figure 4d presents a quantitative
analysis of MVD of xenografts transplanted into host mice with
(open circles), or without (closed circles), androgen stimulation.
The MVD was decreased 60% on Day 14 in human prostate
xenografts transplanted into hosts that lacked circulating testicular
androgen.
The vascular network of primary xenografts rapidly become
patent with the host vasculature, as demonstrated by labeling of
endothelial cells of the xenograft vessels with biotinylated
Lycopersicon esculentum lectin [23] administered systemically to the
host by tail vein injection. On Day 4 post-transplantation, access of
the angiogenic vessels to systemically available lectin was limited,
as demonstrated by an absence of lectin within the xenografts
(Fig. 5b). The number of lectin-stained vessels increased markedly
between Days 7 and 10 after transplantation, which demonstrated
the vascular network of the xenografts, including the vessels newly
formed by angiogeneis, was patent with the host circulation and
available to systemically injected lectin (Fig. 5c, d). Importantly,
there was significant leakage of lectin into the interstitial tissue
space surrounding the neo-vessels (Fig. 5c, d). Even as late as Day
14 after transplantation, when endothelial cell proliferation largely
had ceased, the newly formed vessels leaked systemically
administered lectins into the interstitial tissue space (Fig. 5e).
However, on Day 30 after transplantation, lectin leakage into the
interstitial space was absent, suggesting vascular maturation
(Fig. 5f). Recruitment and association of alpha-smooth muscle
actin (a-SMA) positive peri-endothelial cells (mural cells or
pericytes) with the vascular endothelial cells is a marker of
vascular maturation (lack of angiogenic activity) and vascular
integrity [8,11,24]. Therefore, the absence of lectin leakage in the
primary xenografts on Day 30 after transplantation was antici-
pated to be correlated with association of the neo-vasculature with
a-SMA expressing cells. a-SMA expressing peri-endothelial cells
were not associated with endothelial cells during the interval of
active angiogenesis (Days 5 to 15 post-transplantation) (Fig. 5h)
when the vessels had irregular, jagged contours, and leaked lectin
into the interstitial spaces (Fig. 2b, 5c–e). In contrast, endothelial
Figure 2. Primary xenografts of human prostate tissue undergo
an explosive increase in human vessels over the initial 14 days
after tissue transplantation. (a–b). Endothelial cells in primary
xenografts of prostate tissue identified by human CD31 immuno-
labeling and visualized by confocal laser scanning microscopy in initial
tissue specimens (IT), and in primary xenografts of prostate tissue on
Day 14 after tissue transplantation (d14). (c). Dual-immuno-histochem-
ical staining with species-specific anti-human and anti-mouse CD31
antibodies in primary xenografts of prostate tissue on Day 14 after
implantation. Human CD31 expression was visualized using FITC-
labeled goat-anti-mouse IgG. Mouse CD31 expression was visualized
using Cy3-labeled sheep-anti-rat IgG.
doi:10.1371/journal.pone.0029623.g002
Figure 3. Time course of angiogenic activity in primary xenografts of human prostate. (a–g) Immuno-histochemical identification of
blood vessels in initial tissue specimens before transplantation (IT), and in corresponding primary xenografts of prostate tissue during the fourteen
days after transplantation (d1–d14). (h). Quantification of MVD in primary xenografts of prostate tissue, and RCC tissue, over the 14 days after tissue
transplantation. MVD was quantitated by immuno-staining with anti-human CD31. (i). Quantification of MVD in prostate and renal tissue xenografts
represented by fold-increase in human-CD31 positive cells in primary xenografts of prostate tissue, and RCC, on Day 14 (diagonal lines bars) and Day
30 (horizontal lines bars) after tissue transplantation, compared to the IT (solid bars). Bars=50 mm.
doi:10.1371/journal.pone.0029623.g003
Angiogenesis in Human Prostate Xenografts
PLoS ONE | www.plosone.org 5 January 2012 | Volume 7 | Issue 1 | e29623cells of the microvasculature in prostate xenografts on Day 30
post-transplantation were associated with a-SMA expressing
mural cells (Fig. 5i), similar to the vasculature in the initial
surgical tissue specimens (Fig. 5g). The decline in active
endothelial cell proliferation, the association of the endothelial
cells with mural cells, and the lack of lectin/fibrin/fibrinogen
leakage into the interstitial tissue space suggested maturation and
stabilization of the neo-vasculature occurred between Days 15 and
30 post-transplantation.
The Angiogenic Burst in Primary Xenografts of Human
Prostate Tissue is Preceded by Up-regulation of VEGF-A
in the Stromal Compartment
The expression pattern of a select group of pro-angiogenic
factors was characterized in human prostate xenografts using PCR
analysis of mRNA isolated on different days after transplantation.
Figure 6a presents the analysis of temporal changes after
transplantation in mRNA expression of the pro-angiogenic factors
VEGF-A, bFGF, IL-8, IL-6, TGF-b and IGF-1. Expression of all
of the pro-angiogenic factors was detected in the matched initial
tissue specimens before transplantation; however, transcripts were
present at varying levels. Among these pro-angiogenic factors,
VEGF-A demonstrated the strongest induction of expression in
xenografts after transplantation into the androgenic environment
of mouse hosts supplemented with exogenous testosterone. VEGF
mRNA was expressed at very low levels in initial tissue specimens
before transplantation, however, mRNA levels increased rapidly
after transplantation, peaking on Day 2 (Fig. 6a).
IHC analyses of histologic specimens of initial prostate tissue
specimens before transplantation, and the correlated prostate
xenografts from the same surgical specimen harvested at different
days post-transplantation, demonstrated the pattern of mRNA
expression for the selected pro-angiogenic factors was reflected at
the protein level. Consistent with the PCR analyses, minimal
differences were found in protein levels for bFGF, IL-8, IL-6,
TGF-b and IGF-1 in the human prostate xenografts compared to
the initial tissue specimens (data not shown). However, levels of
VEGF-A protein increased dramatically in response to transplan-
tation. VEGF-A proteins levels peaked on Day 4 after transplan-
tation, and returned to pre-transplantation levels by Day 8
(Fig. 6b). The rapid up-regulation of VEGF-A protein was
localized largely to the stromal compartment of the human
prostate xenografts; therefore the peak of stromal VEGF-A protein
expression clearly preceded the wave of angiogenesis by human
endothelial cells, which began after Day 5 (Fig. 3b; Fig. 3h, open
circles). Consistent with previous reports that androgen regulated
VEGF expression [12,25], VEGF protein was induced to a
substantially greater level in xenografts transplanted to mouse
hosts implanted with testosterone pellets (Fig. 6b, +T).
Oxygen availability within tissue is an important regulator of
angiogenesis; hypoxia is one of the most potent stimuli for VEGF
expression and angiogenesis [26,27]. The hypoxic response is
mediated through stabilization of hypoxia inducible factors HIF-
1a and HIF-2a, and results in up-regulation of expression of
VEGF, the most prominent target gene of the HIFs [26,27]. To
determine whether the wave of VEGF expression, and subsequent
Figure 4. Dependence on androgen stimulation of proliferative activity of human endothelial cells in primary xenografts of human
prostate tissue. (a). Co-localization of huCD31 (red) and Ki-67 (brown) protein demonstrated the increased presence of vessels with proliferatively
active endothelial cells over the 14 days after tissue transplantation (d2–d14). (b). Quantification of the complete image set is presented in (a). Values
were expressed as a percentage of total vessels that contained at least one Ki-67-positive endothelial cells. Bars=10 mm. (c). Immuno-histochemical
identification of human blood vessels in initial tissue (IT) specimens before transplantation, and in corresponding primary xenografts on Day 14 after
tissue transplantation. The host mice were pre-implanted with, or not implanted with, sustained-release testosterone pellets. (d). Quantification of
MVD in prostate xenografts over the 14 days after tissue transplantation into animals pre-implanted with (open circles), or not implanted with (closed
circles), sustained-release testosterone pellets.
doi:10.1371/journal.pone.0029623.g004
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with hypoxia that resulted from surgical excision and transplan-
tation, mice were administered the hypoxia marker pimonidazole
(Hydroxyprobe-1TM) by i.p injection at different times after
transplantation of the prostate xenografts. After incubation to
allow bio-distribution and tissue sequestration of pimonidazole in
areas of hypoxia, xenografts were harvested and analyzed using
IHC for localization of pimonidazole, and for analysis of protein
levels of HIF-1a, HIF-2a and the hypoxia regulated gene,
GLUT1. During the interval where stromal up-regulation of
VEGF expression was apparent (Days 1 to 6 post-transplantation),
areas of hypoxia were not observed in the xenografts, and HIF-
Figure 5. Vascular integrity and maturation of newly formed vessels in primary xenografts of human prostate tissue. (a–f).
Immediately before xenograft harvest, the neo-vasculature in human prostate xenografts was labeled in vivo with biotin-conjugated lectin injected
i.v. into the host mice. In vivo labeling studies demonstrated anastomosis of the prostate vasculature to the host vasculature by Day 7 after
transplantation, and maturation of the human neo-vasculature by Day 30 after transplantation. (g–i). Confocal laser scanning microscopic
visualization of dual-immuno-labeling of alpha-smooth muscle actin (aSMA, green) and huCD31 (red). Endothelial cells were associated with aSMA-
positive peri-endothelial cells (indicated by arrowheads) on Day 30 post-transplantation.
doi:10.1371/journal.pone.0029623.g005
Figure 6. The angiogenic burst in primary xenografts of prostate tissue is preceded by androgen-modulated up-regulation of
VEGF-A gene expression in the stromal compartment. (a). PCR analysis of expression of transcripts for pro-angiogenic factors in initial prostate
tissue specimens before transplantation, and in corresponding primary xenografts after transplantation. Total RNA was extracted from initial prostate
tissue (IT), and from prostate xenografts on different days after transplantation (d1–d14). GADPH was used as an internal control. (b). Immuno-
histochemical identification of human VEGF protein in primary xenografts of prostate tissue over the 14 days after transplantation (d1–d14) in host
mice pre-implanted with (+T), or not pre-implanted with (2T), sustained-release testosterone pellets. Bars=50 mm.
doi:10.1371/journal.pone.0029623.g006
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(Figure 7). Consequently, hypoxia did not appear to drive the
burst of VEGF expression in the primary xenografts.
Increased Vascularization is Associated with the
Emergence of a Reactive Stroma in Primary Xenografts of
Human Prostate Tissue
In solid tumors, angiogenesis usually is accompanied by multiple
other phenotypic changes in the tissue microenvironment. A
‘‘reactive stromal compartment’’ is a histological hallmark of
invasive carcinomas, and may predict CaP recurrence-free
survival [28]. Furthermore, the processes that lead to the
formation of tumor-associated reactive stroma appear similar to
those that operate at sites of wound healing [29]. To determine if
the dramatic burst of human angiogenesis was associated with
changes in stromal cell phenotype associated with transition to a
reactive stroma, primary xenografts harvested on different days
after transplantation were evaluated for the neo-expression of
fibro-muscular markers and Masson’s trichrome staining that
differentially stains smooth muscle cells (red staining) and collagen
fibers (green staining), indicators of the induction of a reactive
stroma.
Analysis of non-involved areas of fresh prostate surgical
specimens (IT) showed broad expression of a-SMA and Calponin
(early and late smooth muscle markers, respectively), and a
mixture of red-staining smooth muscle cells and green-staining
collagen fibers, which identify a fibro-muscular phenotype (Fig. 8,
IT). Vimentin levels were low throughout the pre-transplantation
stroma, with some vimentin positive cells observed adjacent to
epithelial cell-lined acini. Starting on day 2 post-transplantation,
concurrent with the up-regulation of VEGF-A expression in the
stromal compartment, the smooth muscle cells observed in the
stroma changed to a reactive stroma phenotype. By Day 14, the
stroma showed a significant decrease, or complete loss, of markers
of differentiated smooth muscle cells, and the extracellular matrix
had become composed predominantly of collagen (green staining;
Masson’s trichrome). A limited analysis of the stromal compart-
ment of prostate xenografts at Day 28 after transplantation
demonstrated that, even though collagen deposition remained
marked, expression of the fibroblastic markers characteristic of
reactive stroma was lost, and the stroma had regained expression
of the differentiated-stromal cell markers, a-SMA and calponin. At
28 days post-transplantation, expression of the markers of a fibro-
muscular phenotype had recovered in the stroma of both benign
Figure 7. Determination of hypoxic areas, and of expression of HIF-1a, HIF-2a and GLUT1 in primary xenografts of human prostate.
Animals were administered Hypoxyprobe-1 (HyPo-P, NPI Inc.) via i.p injection (60 mg/100 g body weight) on select days after tissue transplantation.
One hour after injection, the prostate xenografts were harvested and hypoxic areas visualized using a monoclonal antibody specific for Hypoxyprobe-
1. Immuno-histochemical identification of changes in human HIF-1a, HIF-2a and GLUT1 protein levels in primary xenografts of human prostate tissue
over the 4 days after tissue transplantation (1–4). Hypoxic areas, and human HIF-1a, HIF-2a, and GLUT1 protein, were visualized using DAB and
hydrogen peroxide.
doi:10.1371/journal.pone.0029623.g007
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observed in the initial tissue (Fig. S1). Interestingly, these changes
were prostate tissue-specific events since they were not observed in
primary xenografts of human kidney tissue (Fig. S1). These results
suggested that transplantation induced tissue-specific, and transi-
tory, activation of the stroma of the primary xenografts of human
prostate tissue, eliciting a transformation to a reactive stroma, with
features similar to tumor-associated stroma.
Discussion
The search for, and validation of, anti-angiogenic and
chemotherapeutics treatments for localized prostate cancer has
been handicapped by the lack of pre-clinical models that allow
evaluation of candidate drugs in the context of an intact tissue
microenvironment. The heterotypic signaling between cancer cells
and the different cell types within the tumor microenvironment
governs much of the biology of carcinomas, and experimental
models that do not recapitulate this key component generate
tumors that are biologically very different from those found in
human cancer patients. For this reason, the ability of xenografts
generated from cell lines propagated in culture to predict the
response of tumors in patients to anti-cancer drugs is limited
[30,31]. This is particularly important in the arena of anti-
angiogenic therapies. The essential role that VEGF-A plays in the
neo-vascularization of malignant tissues has led to the emergence
of anti-VEGF drugs as a panacea for the treatment of all tumors,
regardless of the tissue of origin, based on studies in cell line-based
xenografts. However, these promising results have not been
observed in clinical studies [32,33,34].
Tumors in human patients exhibit intrinsic resistance to anti-
VEGF therapy, or rapidly acquire resistance to anti-VEGF
treatment, developing compensatory mechanisms to circumvent
the anti-angiogenic agent. Mechanisms for adaptation to anti-
VEGF treatment seem to be diverse, and new evidence suggests
that tumor stromal cells (including endothelial cells) may be active
players in the resistance to anti-VEGF therapy [35,36,37].
Consequently, the presence of mouse stromal and endothelial cell
compartments in human cell line-based tumors represents a model
not representative of human tumors in situ.
Recently, our group using the primary prostate xenograft model
demonstrated that androgen deprivation, the standard treatment
for locally advanced or metastatic prostate cancer, induced rapid
involution and recovery of human prostate [38]. The acute
apoptotic and reparative events in the human vasculature in
primary xenografts induced by androgen deprivation were not
observed in either the rat prostate or in human cell line-based
xenografts, but is present in human subjects [39,40]. The accurate
recapitulation by the human prostate primary xenografts of the
human prostate in situ could result in identification of more
effective treatments for advanced CaP.
The human prostate primary xenografts utilized in these studies
present many unique advantages as a pre-clinical model: 1)
primary xenografts of benign and malignant human prostate are
established with high efficiency from fresh human surgical tissue
specimens; 2) a florid angiogenic response by endogenous human
endothelial cells is elicited during establishment of xenografts of
both CaP and benign human prostate tissue; 3) the xenografts
maintain human prostate tissue architecture, and 4) after
establishment, the proliferation/apoptotic rates in xenografts
recapitulate those of the original tissue for at least 60 days after
transplantation [18]. The angiogenic wave by human endothelial
cells that produces the significant increase in MVD in primary
xenografts human prostate [17] allows in vivo modeling of human
angiogenesis/neo-vascularization occurring within an intact hu-
man prostate tissue microenvironment. However, a limitation of
the primary xenograft model is that neither the benign nor cancer
xenografts are amenable to serial passage from host to host animal.
Figure 8. Induction of a reactive stroma in primary xenografts of human prostate tissue. Temporal changes of protein levels of VEGF,
aSMA, Calponin and Vimentin were measured by IHC-staining, and of the presence of smooth muscle cells and collagen fibers was visualized by
Masson’s trichrome staining, over the 14 days following xenograft transplantation. a-SMA and Calponin are early and late markers of smooth muscle,
respectively. Masson’s trichrome identifies smooth muscle cells (purple) and collagen fibers (green).
doi:10.1371/journal.pone.0029623.g008
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the homeostasis, and angiogenesis, of human prostate vasculature
within an intact human prostate tissue microenvironment, the
studies are not compromised by the limitation that they are
confined to the primary (first) transplantation. Offsetting this
limitation is the capacity to confirm the inter-patient universality
of observations by analysis through xenografts derived from
multiple independent patients.
The hypothesis that the increase in MVD was the result of
angiogenesis by pre-existing human vessels is validated by the
increased number of proliferating human endothelial cells
observed during the initial days after transplantation, immediately
preceding the increase in MVD. Recent reports have proposed
that a significant portion of endothelial cells involved in formation
of new vasculature are circulating endothelial stem/progenitor
cells (EPCs) that are mobilized from the bone marrow (BM) by
increased levels of circulating VEGF [41]. The circulating
progenitor cells are recruited to growing or damaged vasculature,
incorporate into the vasculature at the peripheral site, and
differentiate into mature endothelial cells [42]. However, in the
human prostate primary xenograft model, endothelial cells of host
origin were not observed to be co-localized with the human
endothelial cells in the neo-vasculature of the xenografts. This
indicates, that in this model, BM-derived circulating EPCs of host
origin do not contribute significantly to the genesis of the neo-
vasculature in the xenografts. It is noteworthy that, despite the
large increase in VEGF protein in the stromal compartment
following transplantation, there was no concomitant increase in
the level of circulating VEGF protein during the period of
angiogenesis (data not show). This suggests a possible explanation
for the lack of recruitment of host BM-derived endothelial
precursors. However, human BM-derived endothelial precursors,
or vascular progenitors resident in the human prostate tissue at the
time of transplantation, may contribute to the observed neo-
vascularization.
The lack of areas of hypoxia within prostate xenografts
following transplantation, but before anastomosis of the xenograft
microvasculature to the host vascular network, is a unique finding.
The intra-vital lectin studies revealed that xenograft microvascu-
lature was not patent with the host circulation until after Day 4
following transplantation. Nonetheless, the lack of necrosis in the
center of the xenografts, and the maintenance of expression of the
androgen-regulated proteins AR and PSA over the entire fourteen
days time-course after transplantation, suggested that the small
size of the xenografts (less than 2 mm cubed) allowed efficient
diffusion of oxygen and androgen from the host circulation into
the xenograft before anastomosis. Additionally, the architectural
pattern of the up-regulation of VEGF-A expression (from the
periphery of the xenografts toward the center) also suggested that
the signals that induced the burst of VEGF expression were not
hypoxia mediated.
An alternative mechanism for regulation of VEGF expression in
the prostate xenografts was suggested by reports that VEGF
expression in human prostate is androgen-regulated [8,11,12].
The prostate gland is an androgen-sensitive organ, and many of
the cell types in prostate demonstrate AR-transactivation of gene
transcription, including endothelial cells [15]. Consequently,
perturbation of the androgenic milieu of the prostate may result
in modulation of the entire tissue microenvironment, including
endothelial cell homeostasis and angiogenesis [43]. A direct role
for androgen in modulation of stromal VEGF expression was
validated by our demonstration that VEGF expression by stromal
cells was induced to a substantially greater level in xenografts
transplanted to mouse hosts implanted with testosterone pellets
(Figure 6B). Furthermore, we reported recently that human
prostate endothelial cells express functional AR, and that
androgen modulates proliferation of human prostate endothelial
cells through an AR-dependent mechanism [15]. Consequently,
androgens may affect proliferation of human prostate endothelial
cells in vivo by both direct (endogenous AR-mediated) and indirect
(paracrine VEGF from stroma) mechanisms. This hypothesis is
reinforced by our observations that endothelial cells from human
kidney tissue lack of expression of AR, and kidney xenografts do
not demonstrate of up-regulation of VEGF after transplantation.
VEGF-A over-expression by tumor cells leads to the formation
of nascent tumor blood vessels of exaggerated size, tortuosity, and
permeability [8,44,45]. VEGF-A over-expression also is capable of
inducing formation of tumor-like blood vessels in normal tissue in
the absence of tumor cells [46,47,48]. The neo-vessels produced
in the primary prostate xenografts during the angiogenic wave
that follows the induction of stromal VEGF-A expression are
abnormal, resembling those observed in malignant tissues [8,44,
45,46]. Furthermore, cessation of stromal VEGF expression
preceded the cessation of vascular leakage and the recruitment
of mural cells to the endothelial cells associated with maturation
and stabilization of neo-vasculature, consistent with the pro-
angiogenic properties of VEGF [49]. Consistent with these
observations, reports suggest that tumor vessels that lack adequate
pericyte coverage are more vulnerable to anti-angiogenic therapy
[8,50], and that dual targeting of endothelial cells and pericytes
improves therapeutic efficacy in a variety of mouse tumor models
[50,51,52]. Consequently, the well-defined time windows in the
human prostate xenografts for angiogenesis, anastomosis to the
host vasculature, and maturation of the human vasculature,
marked by loss of leakage and association with mural cells, suggests
the model may provide a unique pre-clinical tool to study further
the relationship between vessel maturation and the anti-tumor
efficacy of candidate anti-angiogenic agents, and combinations of
agents.
A key role for the stromal compartment in mediation of
angiogenesis in the human prostate is suggested by this study.
Studies of human breast, colon, and prostate cancers have
demonstrated that increased MVD within the stromal compart-
ment is a common component of cancer progression [53,54,55,
56]. Additionally, the stromal compartment of these cancers
exhibit a reactive stromal phenotype associated with expression of
a novel spectrum of extracellular matrix (ECM) components
compared to the stroma of benign tissue. The term ‘‘carcinoma
associated fibroblasts’’ (CAFs) has been used to describe this
reactive phenotype [53,54]. However, little is known about the
molecular events that govern the conversion of a benign fibro-
muscular stroma into a carcinoma-associated stroma. Analysis of
gene expression patterns of CAFs demonstrated strong similarities
between these cells and the fibroblasts present at sites of active
tissue repair, such as in the wound healing process [57], and
experimental models support a role for TGF-b signaling in this
progression [56,58]. During the establishment of primary
xenografts of both CaP tissue and its benign counterpart, increased
collagen deposition and vimentin expression were observed, with a
loss of a-SMA, Calponin and Desmin expressing cells, features
associated with the appearance of a reactive stroma phenotype in
human prostate tissue in situ [28]. The common response of the
stromal compartment of both benign and malignant prostate tissue
suggests that up-regulation of VEGF expression is an innate
response to stress, possibly similar to the well-characterized
stromal response to tissue damage. Increased expression of VEGF
has been reported in other models of transplantation, such as in
mouse allografts, and at sites of transplantation of tissue from
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undergoing surgery for removal of primary tumors can exhibit a
burst of VEGF synthesis at the wound site after surgery;
importantly, over-expression of VEGF in the healing breast was
localized mainly in the stromal compartment [62]. Furthermore,
the potential role of VEGF as a promoter of tumor angiogenesis,
as well as tumor stromagenesis, has been suggested previously
[63]. Even though our data do not demonstrate that VEGF-A up-
regulation is the sole causal factor driving the transition from a
benign fibro-muscular phenotype to a reactive stroma, the link
cannot be completely discarded based on the facts that: 1) VEGF
expression was drastically, but not totally, reduced in the absence
of androgen and that the threshold concentration of VEGF
necessary to induce angiogenesis, or stromagenesis, could be
different in the absence of androgen, and 2) the pattern of
expression of the stromal markers reverted to the pattern observed
in the initial prostate tissue concurrent with the cessation of
angiogenic activity.
Summary and Conclusions
During the course of this analysis a study was reported by Pinto
et al. [64] that VEGF secreted by a reactive stromal cell line (BJ3Z)
isolated from mammary gland enhanced angiogenesis and
hormone-independent growth of estrogen receptor-positive breast
cancer xenografts. In our study, however, transplantation of both
human benign and malignant prostate tissue set in motion a chain
of events within the stromal compartment that led to generation of
a reactive stroma and angiogenesis (Fig. 9). The burst of stromal
VEGF-A was unexpected, and suggested that up-regulation of
VEGF-A expression was an innate response of the human prostate
stroma cells, similar to the stromal response to tissue damage [29],
a response that possibly could contribute to the appearance of the
reactive stroma. Interestingly, the angiogenic response in primary
xenografts of human prostate tissue was ‘‘activated’’ by, but not
‘‘dependent’’ on, the presence of circulating androgens. The
proposed sequence and timeframe for these processes were: 1) up-
regulation of VEGF (peaking at Days 2–4 after transplantation), 2)
angiogenesis (peaking at Day 7 after transplantation), and 3)
generation of reactive stroma (plateauing after Days 10–14 after
transplantation) (Fig. 9a). Based on this reproducible sequence of
events, two hypothetical models can be proposed to explain the
role of VEGF-A in the temporal occurrence of these processes
(Fig. 9b). In the first model, tissue transplantation induces up-
regulation of VEGF-A directly, which activates both angiogenesis
and the appearance of reactive stroma. In the second model,
generation of reactive stroma by prostate tissue occurs by a tissue
transplantation-induced mechanism that is completely indepen-
dent of the up-regulation of VEGF-A and/or mechanisms
stimulating angiogenesis. In the second model, the temporal
difference between tissue transplantation and the appearance of a
reactive stroma could suggest participation of a transplantation-
induced unknown intermediary factor(s) in the generation of
reactive stroma. Elucidation of the microenvironmental mecha-
nism(s) responsible for initiating and driving the angiogenic
response, and/or reactive stroma generation, might have broad
application in understanding the development and progression of
CaP, and other tumors. However, more analyses are necessary to
elucidate the role of VEGF signaling in generation of a reactive
stroma, studies that could identify new therapeutic targets to
effectively counteract progression of CaP, and potentially other
hormonally responsive tumors.
Supporting Information
Figure S1 Induction of a reactive stroma in primary
xenografts of human prostate and kidney tissues.
Temporal changes in protein levels of aSMA and Calponin were
measured by evaluation of IHC-staining and collagen fibers
visualized by Masson’s trichrome staining in initial prostate tissue
(IT) and prostate xenografts on different days after transplantation
(d4, d14, d28).
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